United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
608.49
+7.17 (1.19%)
Nov 4, 2026, 4:00 PM EST - Market closed
United Therapeutics Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, United Therapeutics stock has a consensus rating of "Buy" and an average price target of $670.93. The average 1-year stock price forecast is 10.26% higher than the current stock price, while the lowest is $368 (-39.52%) and the highest is $850 (+39.69%).
Price Target: $670.93 (+10.26%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for United Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 1 | 1 |
| Total | 15 | 15 | 15 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $710 → $695 | Buy | Reiterates | $710 → $695 | +14.22% | Oct 28, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $700 → $850 | Buy | Maintains | $700 → $850 | +39.69% | Oct 26, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $708 → $697 | Buy | Reiterates | $708 → $697 | +14.55% | Oct 22, 2026 |
| Raymond James | Raymond James | Buy Maintains $685 → $717 | Buy | Maintains | $685 → $717 | +17.83% | Oct 20, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $685 → $725 | Buy | Reiterates | $685 → $725 | +19.15% | Oct 19, 2026 |
Financial Forecast
Revenue This Year
3.18B
from 3.18B
Decreased by -0.14%
Revenue Next Year
3.60B
from 3.18B
Increased by 13.42%
EPS This Year
28.02
from 27.86
Increased by 0.57%
EPS Next Year
33.89
from 28.02
Increased by 20.94%
EPS and Forward PE are based on non-GAAP adjusted numbers.